Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN ...Middle East

OSLO, Norway, Feb. 22, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that the international multicenter Phase III clinical study of Cevira® (APL-1702), the non-surgical...

Hence then, the article about photocure partner asieris to present first ever results of the international multicenter phase iii clinical study for cevira a non surgical treatment for cervical hsil at the 2024 eurogin was published today ( Thursday 22/02/2024 - 10:57 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN )

Also on site :

• Israel assisted in US rescue mission of downed airman in Iran
• Japan should lead efforts toward U.S.-Iran ceasefire
• Crew member from downed US fighter jet rescued in 'miraculous' operation, says Trump